Results 81 to 90 of about 8,073 (209)

Clinical and preclinical treatment of urologic diseases with phosphodiesterase isoenzymes 5 inhibitors: an update

open access: yesAsian Journal of Andrology, 2016
Phosphodiesterase isoenzymes 5 inhibitors (PDE5-Is) are the first-line therapy for erectile dysfunction (ED). The constant discoveries of nitric oxide (NO)/cyclic guanosine monophosphate (cGMP) cell-signaling pathway for smooth muscle (SM) control in ...
Wen-Hao Zhang, Xin-Hua Zhang
doaj   +1 more source

Heart–Lung Interactions in Pulmonary Hypertension due to Heart Failure With Preserved Ejection Fraction

open access: yesComprehensive Physiology, Volume 16, Issue 3, June 2026.
This review considers heart–lung interactions in pulmonary hypertension due to heart failure with preserved ejection fraction across scales, including organ, tissue, and cell scales. Key knowledge gaps in preclinical disease models, tools for clinical phenotyping, and underlying biological mechanisms are identified for future studies.
Pratima Prabala   +2 more
wiley   +1 more source

Determination of phosphodiesterase 5 (PDE5)inhibitors in instant coffee premixes using liquid chromatography-high-resolution mass spectrometry (LC-HRMS) [PDF]

open access: yes, 2019
© 2019 Elsevier B.V. As a widely consumed beverage, coffee tends to be a target for intentional adulteration. This study describes the application of modified quick, easy, cheap, effective, rugged, and safe (QuEChERS)coupled to liquid chromatography-high-
Fu, S, Xiao, L, Mohd Yusop, AY
core   +1 more source

Harnessing Phytochemicals for Brain Cancer Therapy: Insights Into Medulloblastoma and Glioblastoma Treatment

open access: yesPhytochemical Analysis, Volume 37, Issue 4, Page 507-535, June 2026.
ABSTRACT Primary brain tumors are life‐threatening diseases. Glioblastoma is the most aggressive type with a poor prognosis. Medulloblastoma is the most common pediatric brain tumor. While surgical treatments often result in recurrences owing to the complex nature of the tumor microenvironment, conventional treatments lower the quality of life of ...
Ilkay Irem Ozbek   +3 more
wiley   +1 more source

The Association between PDE5 Inhibitors and Aneurysm/Arterial Dissection : A Pharmacovigilance Study Using WHO Safety Database [PDF]

open access: yes
Aneurysm and arterial dissection have been reported as adverse drug events, associated with angiogenesis inhibitors and fluoroquinolones. Specifically, several cases of severe arterial disease following cGMP-specific phosphodiesterase type 5 (PDE5 ...
80848367   +53 more
core  

Nebivolol potentiates the efficacy of PDE5 inhibitors to relax corpus cavernosum and penile arteries from diabetic patients by enhancing the NO/cGMP pathway. [PDF]

open access: yes, 2014
INTRODUCTION: The efficacy of oral pharmacotherapy for erectile dysfunction (ED) (i.e., type 5 phosphodiesterase[PDE5] inhibitors) is significantly reduced in diabetic patients. Nebivolol is a selective β1-blocker used for treatinghy pertension that has
Martínez-Salamanca, J   +6 more
core  

Sympatho‐Excitation in Pulmonary Hypertension: The Potential Role of Pulmonary Arterial Baroreceptors: An Acute Physiologic Intervention Study

open access: yesRespirology, Volume 31, Issue 6, Page 621-629, June 2026.
Pulmonary arterial baroreceptors reflexively stimulate sympathetic nerve activity (SNA) in response to elevated pulmonary artery pressure and distension. In pulmonary hypertension patients, changes in muscle SNA were proportional to changes in pulmonary haemodynamics following nebulised iloprost.
Michael J. Plunkett   +6 more
wiley   +1 more source

N-3-Substituted Imidazo Quinazolinones: Potent and Selective PDE5 Inhibitors As Potential Agents for Treatment of Erectile Dysfunction [PDF]

open access: yes, 2000
Phosphodiesterase type 5 (PDE5) inhibitors with improved PDE isozyme selectivity relative to sildenafil may result in agents for the treatment of male erectile dysfunction (MED) with a lower incidence of PDE-associated adverse effects.
Sun, Zhong   +7 more
core   +1 more source

Non-invasive management of primary phosphodiesterase type 5 inhibitor failure in patients with erectile dysfunction

open access: yesTherapeutic Advances in Urology, 2009
Phosphodiesterase type 5 inhibitors (PDE5-i) have become first line therapy for the treatment of erectile dysfunction. Most initial prescriptions for PDE5-i are by primary care practitioners.
Gregory Lowe MD, Robert Bahnson
doaj   +1 more source

Tadalafil once daily in the management of erectile dysfunction: patient and partner perspectives

open access: yesPatient Preference and Adherence, 2009
Pierre Costa1, Thierry Grivel2, Naji Gehchan31Service d’Urologie–Andrologie, Hôpital Caremeau, Nîmes, France; 2159, Avenue Sainte-Marguerite, Nice, France; 3Eli Lilly and Company, Lilly France – Medical ...
Pierre Costa   +2 more
doaj  

Home - About - Disclaimer - Privacy